Tianeptine — Safety, Research, Risks & Legal Status

Not medical advice. Tianeptine is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	Coaxil, Stablon, selective serotonin reuptake enhancer, SSRE
Category	Research Chemical
french_approval	Approved as Coaxil and Stablon in France since early 1980s
opioid_receptor	Recent research shows mu-opioid receptor activation at higher doses
addiction_liability	Reports of rapid dependence exceed typical antidepressants
US legal status	Approved as an antidepressant in some countries (France, Russia, Poland) but NOT approved by the FDA in the US. Sold as a research chemical in the US and online; not a controlled substance federally but some states may regulate. Regulatory status uncertain and evolving.

What is Tianeptine?

Tianeptine is a tricyclic-like compound initially marketed as an atypical antidepressant that enhances serotonin reuptake (opposite to SSRIs) and may modulate mu-opioid and NMDA receptor function. Its exact mechanism of action remains incompletely understood.

How it works

Enhances serotonin reuptake (inverse of SSRIs) and activates mu-opioid receptors at higher doses. May modulate NMDA-receptor function and affect dopamine systems, explaining both mood effects and addiction liability.

Background & history

Developed in France in the 1980s as an antidepressant and marketed under Coaxil and Stablon brands. Approved in France, Russia, and Poland. Emerged in Western research-chemical markets in the 2000s with growing reports of abuse potential.

What the research says

Limited controlled human studies show some efficacy in depression and anxiety comparable to conventional antidepressants. Recent research suggests mu-opioid receptor involvement and potential addiction liability. Evidence for cognitive benefits is weak and anecdotal.

Reported effects

Studied for mood elevation and anxiety reduction in depression trials
Reported cognitive improvements (concentration, focus) in small studies, but evidence is mixed
Reported stimulant-like effects at higher doses (anecdotal, dose-dependent)
Studied for potential anxiolytic and stress-reducing properties
Reported euphoria and reinforcing effects at higher doses (suggests opioid-like activity)

Dosing & administration (informational)

Harm-reduction information only: users report highly variable dose escalation patterns, with some developing tolerance rapidly. Addiction resembles opioid dependence more than traditional antidepressants.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

SERIOUS DEPENDENCE RISK: Many users report rapid tolerance, escalation, and addiction-like behavior; withdrawal can cause dysphoria, fatigue, and opioid-like withdrawal symptoms
Hepatotoxicity case reports exist; liver monitoring advised
Interactions with SSRIs, tramadol, and opioids increase serotonin syndrome and overdose risk
Quality control is poor in research-chemical supply; potency and purity highly variable
Contamination with other compounds reported in underground markets

Drug & supplement interactions

SSRIs, SNRIs (serotonin syndrome risk)
Opioid medications (additive effects and overdose risk)
Tramadol (serotonin syndrome and seizure risk)
Monoamine oxidase inhibitors (dangerous serotonin elevation)
Alcohol (increased hepatotoxicity risk)

Who should avoid it

Concurrent use with SSRIs or other serotonergics
Opioid co-use (overdose and combined addiction risk)
Alcohol consumption (liver damage risk)
Abrupt cessation (withdrawal and relapse risk)
High-dose use (euphoria and addiction risk substantially increase)

How it is commonly combined

Do not combine with SSRIs, SNRIs, opioids, or other serotonergics due to serotonin syndrome and overdose risks.

Legal & regulatory. Approved as an antidepressant in some countries (France, Russia, Poland) but NOT approved by the FDA in the US. Sold as a research chemical in the US and online; not a controlled substance federally but some states may regulate. Regulatory status uncertain and evolving.

Quality & harm reduction

S
e
e
k
t
h
i
r
d
-
p
a
r
t
y
C
o
A
v
e
r
i
f
y
i
n
g
p
u
r
i
t
y
(
t
i
a
n
e
p
t
i
n
e
s
o
d
i
u
m
v
s
.
f
r
e
e
b
a
s
e
)
;
p
o
t
e
n
c
y
c
l
a
i
m
s
o
f
t
e
n
i
n
f
l
a
t
e
d
.
A
v
o
i
d
s
u
p
p
l
i
e
r
s
l
a
c
k
i
n
g
t
e
s
t
i
n
g
d
o
c
u
m
e
n
t
a
t
i
o
n
o
r
w
i
t
h
i
n
c
o
n
s
i
s
t
e
n
t
q
u
a
l
i
t
y
r
e
p
o
r
t
s
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Is tianeptine safe for long-term use?

Long-term safety is poorly studied. Case reports and user accounts suggest dependence and withdrawal can develop, particularly at higher doses or with frequent use.

How does tianeptine compare to prescription antidepressants?

Limited head-to-head trials exist. In some studies, tianeptine showed efficacy similar to tricyclic antidepressants for depression, but its abuse potential and dependence liability are significant concerns.

Can you overdose on tianeptine?

Overdose is possible and may present with opioid-like symptoms (respiratory depression, sedation, miosis). No specific antidote exists; management is supportive.

What is tianeptine withdrawal?

Withdrawal can include dysphoria, anxiety, fatigue, and joint pain, often described as opioid-like. Duration and severity depend on dose and duration of use.

Why does tianeptine have such high addiction potential?

Mu-opioid receptor activation combined with mood-lifting effects and rapid tolerance creates strong reinforcement and dependence comparable to opioids, distinct from traditional antidepressants.

References & further reading

F
r
e
n
c
h
c
l
i
n
i
c
a
l
t
r
i
a
l
s
(
C
o
a
x
i
l
/
S
t
a
b
l
o
n
d
e
v
e
l
o
p
m
e
n
t
)
;
r
e
c
e
n
t
m
u
-
o
p
i
o
i
d
r
e
c
e
p
t
o
r
s
t
u
d
i
e
s
;
c
a
s
e
r
e
p
o
r
t
s
o
f
a
b
u
s
e
a
n
d
w
i
t
h
d
r
a
w
a
l
;
o
n
l
i
n
e
h
a
r
m
-
r
e
d
u
c
t
i
o
n
c
o
m
m
u
n
i
t
i
e
s
d
o
c
u
m
e
n
t
i
n
g
a
d
d
i
c
t
i
o
n
p
a
t
t
e
r
n
s
.